← Back to Search

Behavioural Intervention

tDCS for Idiopathic Fallers

N/A
Waitlist Available
Led By Nir Giladi, Prof.
Research Sponsored by Tel-Aviv Sourasky Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1st measure will be taken at baseline ans 2nd immediate post intervention
Awards & highlights

Study Summary

The concurrent performance of two tasks, i.e., dual tasking (DT), is a common and ubiquitous every day phenomena. For example, people frequently walk while talking on a cellphone or drive while talking to a passenger. Often, the performance of one or more of these simultaneously performed tasks may deteriorate when another task is carried out at the same time, even in healthy young adults. This reduction in performance is referred to as the DT deficit or DT cost and is typically much higher in Idiopathic Fallers (IF) than in age-matched controls. In this population the DT cost impairs the gait pattern, as manifested, for example, in increased gait variability, exacerbating instability and fall risk. In the proposed study, would be evaluated the effects of tDCS on dual tasking performance following tDCS. The researchers expect that stimulation of the Pre Frontal Cortex (PFC) (using tDCS) will increase DT performance and prefrontal activation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1st measure will be taken at baseline ans 2nd immediate post intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1st measure will be taken at baseline ans 2nd immediate post intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gait
Secondary outcome measures
Changes in cognitive performance - Executive Function composite score
Frontal lobe

Trial Design

1Treatment groups
Experimental Treatment
Group I: tDCSExperimental Treatment1 Intervention
The active tDCS condition will consist of 4 visit: During each visit, subject will receive a single 20-minute session targeting the prefrontal cortices of either real (1.5 mA) or sham tDCS. Total 4 different targets: Sham motor M1 area motor M1 + Dorsolateral Prefrontal cortex Dorsolateral Prefrontal cortex. The tDCS condition will be randomized and double blinded
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
tDCS
2017
Completed Phase 2
~640

Find a Location

Who is running the clinical trial?

Tel-Aviv Sourasky Medical CenterLead Sponsor
565 Previous Clinical Trials
306,805 Total Patients Enrolled
1 Trials studying Idiopathic Fallers
20 Patients Enrolled for Idiopathic Fallers
Nir Giladi, Prof.Principal InvestigatorTel Aviv Sourasky Medical Center, Tel Aviv, Israel

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Apr 2025